GSK to Acquire BELLUS Health for $2 Billion
GSK has entered into an agreement to acquire BELLUS Health, a Canadian late-stage biopharmaceutical company, for a total consideration of
Read moreGSK has entered into an agreement to acquire BELLUS Health, a Canadian late-stage biopharmaceutical company, for a total consideration of
Read morePlasma protein binding is a phenomenon where drugs bind to proteins in the blood, thereby reducing the concentration of free,
Read moreJapanese multinational pharmaceutical company Shionogi & Co., Ltd,. announced at the beginning of April that the U.S. FDA has granted
Read moreInflaRx N.V., a biopharmaceutical company in the clinical stage of developing anti-inflammatory therapeutics that target the complement system, has announced
Read moreThe potential achievements of personalised medicine and AI in pharma are vast and varied. But moving closer to transforming pharmaceuticals
Read moreMyMD Pharmaceuticals, Inc.®, a clinical stage biopharma company developing groundbreaking therapies for the treatment of serious and debilitating autoimmune and
Read moreReCode Therapeutics, announced the dosing of the first participants in a Phase 1 trial designed to evaluate the safety and
Read moreTZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
Read morePharma giant Pfizer and American biotech company Seagen officially announced on Monday that they have reached a conditional merger agreement
Read moreChicago Headquartered Tempus, pioneering AI-enabled precision medicine, has entered a third strategic collaboration with pharma giant Pfizer, aiming to gather
Read more